Literature DB >> 18794869

New classification of chronic GVHD: added clarity from the consensus diagnoses.

M Arora1, S Nagaraj, J Witte, T E DeFor, M MacMillan, L J Burns, D J Weisdorf.   

Abstract

The Diagnosis and Staging Working Group of the NIH Consensus Development Project on Criteria for Clinical Trials in chronic GVHD (CGVHD) recently proposed criteria for diagnosis and assessment of overall CGVHD severity. We retrospectively reviewed 54 consecutive patients diagnosed with CGVHD between January 2002 and December 2005 after sibling donor transplant to assess the applicability of the new criteria in prognosticating survival and transplant-related mortality (TRM). A total of 8 patients (15%) were reclassified as late onset/persistent or recurrent acute GVHD (late aGVHD), 15 (28%) had overlap syndrome and 31 (57%) had classic CGVHD. Three-year overall survival was worse in patients with late aGVHD (3-year probability 25% (95% CI 4-56%)) followed by overlap syndrome (3-year probability 87% (95% CI 56-96%)) and CGVHD (3-year probability 75% (95% CI 54-87%)); P=0.001. Among patients with overlap syndrome and CGVHD, a trend towards worse survival was seen in patients with severe disease (3-year probability 57.3% (95% CI 21-82%)) as compared to mild+moderate disease (3-year probability 85.1% (95% CI 68-94)); P=0.1. This analysis, undertaken in a contemporary cohort of related donor recipients, indicates that the consensus guidelines are applicable to this population of CGVHD patients.

Entities:  

Mesh:

Year:  2008        PMID: 18794869     DOI: 10.1038/bmt.2008.305

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  34 in total

Review 1.  How we treat chronic graft-versus-host disease.

Authors:  Mary E D Flowers; Paul J Martin
Journal:  Blood       Date:  2014-11-14       Impact factor: 22.113

2.  Comparison of characteristics and outcomes of late acute and NIH chronic GVHD between Japanese and white patients.

Authors:  Yoshihiro Inamoto; Jennifer White; Reiko Ito; Paul J Martin; Giancarlo Fatobene; Ayumu Ito; Takashi Tanaka; Saiko Kurosawa; Sung-Won Kim; Merav Bar; Mohamed L Sorror; Brenda M Sandmaier; Stephanie J Lee; Takahiro Fukuda; Mary E D Flowers
Journal:  Blood Adv       Date:  2019-09-24

3.  Prolonged sirolimus administration after allogeneic hematopoietic cell transplantation is associated with decreased risk for moderate-severe chronic graft-versus-host disease.

Authors:  Joseph Pidala; Jongphil Kim; Melissa Alsina; Ernesto Ayala; Brian C Betts; Hugo F Fernandez; Teresa Field; Heather Jim; Mohamed A Kharfan-Dabaja; Frederick L Locke; Asmita Mishra; Taiga Nishihori; Leonel Ochoa-Bayona; Lia Perez; Marcie Riches; Claudio Anasetti
Journal:  Haematologica       Date:  2015-04-03       Impact factor: 9.941

4.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report.

Authors:  Madan H Jagasia; Hildegard T Greinix; Mukta Arora; Kirsten M Williams; Daniel Wolff; Edward W Cowen; Jeanne Palmer; Daniel Weisdorf; Nathaniel S Treister; Guang-Shing Cheng; Holly Kerr; Pamela Stratton; Rafael F Duarte; George B McDonald; Yoshihiro Inamoto; Afonso Vigorito; Sally Arai; Manuel B Datiles; David Jacobsohn; Theo Heller; Carrie L Kitko; Sandra A Mitchell; Paul J Martin; Howard Shulman; Roy S Wu; Corey S Cutler; Georgia B Vogelsang; Stephanie J Lee; Steven Z Pavletic; Mary E D Flowers
Journal:  Biol Blood Marrow Transplant       Date:  2014-12-18       Impact factor: 5.742

5.  Essential Role of Interleukin-12/23p40 in the Development of Graft-versus-Host Disease in Mice.

Authors:  Yongxia Wu; David Bastian; Steven Schutt; Hung Nguyen; Jianing Fu; Jessica Heinrichs; Changqing Xia; Xue-Zhong Yu
Journal:  Biol Blood Marrow Transplant       Date:  2015-04-04       Impact factor: 5.742

6.  Evaluation of prognostic factors among patients with chronic graft-versus-host disease.

Authors:  Jose A Pérez-Simón; Gabriel Afram; Rodrigo Martino; Jose L Piñana; Teresa Caballero-Velazquez; Olle Ringden; David Valcarcel; Dolores Caballero; Mats Remberger; Yanira de Paz; Jordi Sierra; Jesús San Miguel; Hans Hagglund
Journal:  Haematologica       Date:  2012-02-27       Impact factor: 9.941

7.  Overlap subtype of chronic graft-versus-host disease is associated with an adverse prognosis, functional impairment, and inferior patient-reported outcomes: a Chronic Graft-versus-Host Disease Consortium study.

Authors:  Joseph Pidala; Georgia Vogelsang; Paul Martin; Xiaoyu Chai; Barry Storer; Steven Pavletic; Daniel J Weisdorf; Madan Jagasia; Corey Cutler; Jeanne Palmer; David Jacobsohn; Sally Arai; Stephanie J Lee
Journal:  Haematologica       Date:  2011-11-04       Impact factor: 9.941

8.  Characteristics of chronic GVHD after cord blood transplantation.

Authors:  L F Newell; M E D Flowers; T A Gooley; F Milano; P A Carpenter; P J Martin; C Delaney
Journal:  Bone Marrow Transplant       Date:  2013-04-15       Impact factor: 5.483

9.  Late acute graft-versus-host disease: a prospective analysis of clinical outcomes and circulating angiogenic factors.

Authors:  Shernan G Holtan; Nandita Khera; John E Levine; Xiaoyu Chai; Barry Storer; Hien D Liu; Yoshihiro Inamoto; George L Chen; Sebastian Mayer; Mukta Arora; Jeanne Palmer; Mary E D Flowers; Corey S Cutler; Alexander Lukez; Sally Arai; Aleksandr Lazaryan; Laura F Newell; Christa Krupski; Madan H Jagasia; Iskra Pusic; William Wood; Anne S Renteria; Gregory Yanik; William J Hogan; Elizabeth Hexner; Francis Ayuk; Ernst Holler; Phandee Watanaboonyongcharoen; Yvonne A Efebera; James L M Ferrara; Angela Panoskaltsis-Mortari; Daniel Weisdorf; Stephanie J Lee; Joseph Pidala
Journal:  Blood       Date:  2016-09-13       Impact factor: 22.113

10.  Late Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  Aazim K Omer; Daniel J Weisdorf; Aleksandr Lazaryan; Ryan Shanley; Bruce R Blazar; Margaret L MacMillan; Claudio Brunstein; Nelli Bejanyan; Mukta Arora
Journal:  Biol Blood Marrow Transplant       Date:  2015-12-29       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.